- Acumen Powered by Robins Kaplan LLP®
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
June 17, 2024Emily Tremblay Named IP Rising Star by Euromoney in 2024 Women in Business Law Awards
-
June 17, 2024Three Robins Kaplan Partners Named BTI Client Service All-Stars
-
June 13, 2024Brendan Johnson Named South Dakota Trial Lawyer of The Year
-
June 27, 2024Sex Abuse Litigation
-
June 10-11, 20242024 Probate and Trust Law Section Conference
-
June 11, 2024FBA 2024 Federal Practice Seminar
-
June 2024Robins Kaplan Secures Landmark $7.75 Million Verdict in Aerosol Duster Misuse Case
-
June 2024To Seize or Not to Seize: Campus Protests and Police Uses of Force
-
June 2024Communicating Your Estate Plan: A Helpful Tool, Not a Fix-All
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
Generic Launches
Spring 2020
This chart tracks the date, drug, reference-listed company, applicant, and indications of publicly available drug launches resulting from Abbreviated New Drug Applications and 505(b)(2) Applications.
Reference Listed Drug | NDA Holder | Generic Drug Name | ANDA Applicant(s) |
Indication | Launch Date |
---|---|---|---|---|---|
Neoral | Novartis | cyclosporine | Apotex | used for the prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants | 1/3/2020 |
Silenor | Currax | doxepin | Teva | used to treat insomnia characterized by difficulty with sleep maintenance | 1/3/2020 |
NovoLog/NovoLog Mix | Novo-Nordisk | insulin aspart recombinant | N/A | used to lower blood glucose | 1/7/2020 |
Symbicort | Astra-Zeneca | budesonide / formoterol | Prasco | used as a maintenance treatment in chronic obstructive pulmonary disease (COPD) | 1/8/2020 |
NovoLog/NovoLog Mix | Novo-Nordisk | insulin aspart protamine | N/A | used to lower blood glucose | 1/21/2020 |
Carafate | Allergan | sucralfate | Endo | used to treat and prevent ulcers in the intestines | 1/27/2020 |
Clobex | Micro/Saptalis | clobetasol | N/A | used to treat psoriasis and dermatitis | 1/24/2020 |
Absorica LD | Sun | isotretinoin | N/A | used for the management of severe recalcitrant nodular acne in patients 12 years of age and older | 2/4/2020 |
Syprine | Bausch & Lomb | trientine HCl | Dr. Reddy's | used to treat patients with Wilson's disease who are intolerant of penicillamine | 2/7/2020 |
Marinol | AbbVie | dronabinol | Hetero (Camber) | used to treat nausea and vomiting caused by cancer chemotherapy; also used to treat loss of appetite and weight loss in people with HIV infection | 2/11/2020 |
Moxeza | Novartis | moxifloxacin | Lupin | used to treat conjunctivitis caused by susceptible strains of certain organisms | 2/14/2020 |
Nexium | Astra-Zeneca | esomeprazole magnesium | Hetero (Camber) | used to treat heartburn, gastroesophageal reflux disease (GERD), stomach ulcers, and a damaged esophagus | 2/20/2020 |
Vimovo | Horizon | naproxen / esomeprazole | Dr. Reddy's | used for symptomatic relief of arthritis and esomeprazole magnesium to decrease the risk of developing naproxen-associated gastric ulcers | 2/27/2020 |
Vimovo | Horizon | naproxen / esomeprazole | Lupin | used for symptomatic relief of arthritis and esomeprazole magnesium to decrease the risk of developing naproxen-associated gastric ulcers | 3/5/2020 |
Geodon | Pfizer | ziprasidone | Dr. Reddy's | used to treat occurrences of severe agitation in patients with schizophrenia | 3/17/2020 |
Daraprim | Vyera | pyrimethamine | Dr. Reddy's | used to treat toxoplasmosis when used conjointly with a sulfonamide, since synergism exists with this combination | 3/20/2020 |
Lyrica | Pfizer | pregabalin | Hetero (Camber) | used to treat pain caused by nerve damage due to diabetes or shingles infection | 3/24/2020 |
Adderall XR | Shire | dextroamphetamine saccharate / amphetamine aspartate / dextroamphetamine sulfate / amphetamine sulfate | Lannett | used to treat Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy | 3/31/2020 |
GENERICally Speaking Spring 2020
Related Professionals
Christopher A. Pinahs
Partner
Haroon N. Mian
Associate
GENERICally Speaking Winter 2020
VOL. 9, NO. 4 Related Publications
First Quarter
GENERICally Speaking: A Hatch-Waxman Litigation Bulletin
Oren Langer, Christopher Pinahs, Emily Tremblay, and Christine May
March 25, 2024
Endo Ventures Unlimited Co. v. Nexus Pharms. Inc.
GENERICally Speaking Hatch Waxman Bulletin
March 22, 2024
Mallinckrodt plc v. Airgas Therapeutics LLC
GENERICally Speaking Hatch Waxman Bulletin
March 8, 2024
UCB, Inc. v. Mylan Techs. Inc.
GENERICally Speaking Hatch Waxman Bulletin
March 5, 2024
Genentech, Inc. v. Sandoz, Inc.
GENERICally Speaking Hatch Waxman Bulletin
Related News
October 14, 2022
September 9, 2022
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.